How to Answer Patient Anne Year Questions (Complete Guide)
This question focuses on applying theory to practical scenarios.
What This Question Is About
This question relates to patient anne year and requires a structured academic response.
How to Approach This Question
Focus on explaining concepts clearly and supporting them with examples.
Key Explanation
This topic involves patient anne year. A strong answer should include explanation, application, and examples.
Original Question
PATIENT I Anne L., a 48-year-old woman (5 ft 4 in, 125 lb), reported to her gynecologist that she had been extremely tired, physically weak, and did not have the energy to do her job. Upon questioning, she noted having very heavy menstrual periods lasting for 1 1/2 to 2 weeks. Her hemoglobin was 6.1 g/dL; hematocrit, 19%; MCV (mean corpuscular volume), 70 fL; MCHC (mean corpuscular hemoglobin concentration), 27 g/dL. 4. If Anne is transfused, what would be the recommended component and how many? 5. a. If she is transfused with 3 U of packed cells, what would you estimate her hemoglobin and hematocrit to be following transfusion? b. Would you expect the elevation to be slightly higher or lower than normal based on her size? PATIENT 2 Carl M., a 50-year-old man, was scheduled for a colon resection. The preop orders included a CBC and crossmatch for 2 U. The CBC report was white blood cells (WBCs), 14.5 x 109/L; hemoglobin, 14.0 g/dL; hematocrit, 43%; platelet count, 19,000/uL. The blood bank technologist typed him as 0 positive and cross-matched 2 U of 0-positive packed cells. 6. Is additional component therapy other than the 2-U crossmatch indicated? Why? 7. How many units of the second component should be ordered? 8. Calculate the approximate platelet count following transfusion, assuming a 70-kg man. 9. a. If Carl’s 1-hour post-transfusion platelet count is 40,000/uL, what is his corrected count increment (CCI)? (Assume a body surface area of 1.5 m2.) b. Is it normal, higher, or lower than expected? c. What does this indicate? 10. What are the storage temperature and shelf-life of platelets? PATIENT 3 Melissa G., a 20-year-old woman who had been diagnosed with von Willebrand’s disease, was scheduled for elective surgery. Her physician wanted to stabilize her von Willebrand’s factor (vWF) before surgery and ordered a therapeutic trial of l-deamino-8-D-arginine vasopressin (DDAVP) (Stimate [desmopressin]), a non-blood treatment that increases the release of vWF from storage sites (endothelial lining of blood vessels). She was a weak responder, and her vWF levels did not increase adequately; therefore, the next option was to use blood component therapy. Melissa had approximately 20% of the normal concentration of vWF. 11. What would you expect Melissa’s results to be on the following coagulation tests (increased, normal, or decreased)? a. Prothrombin time (PT) b. Activated partial thromboplastin time (APTT) c. Platelet count d. Bleeding time e. VIII:C f. Ristocetin-induced platelet aggregation (RIPA) 12. Why did the physician try nonblood treatment before ordering blood component replacement therapy? 13. What is/are the component(s) of choice for stabilizing the concentration of vWF?
******CLICK ORDER NOW BELOW AND OUR WRITERS WILL WRITE AN ANSWER TO THIS ASSIGNMENT OR ANY OTHER ASSIGNMENT, DISCUSSION, ESSAY, HOMEWORK OR QUESTION YOU MAY HAVE. OUR PAPERS ARE PLAGIARISM FREE*******."
